Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Kathy W. Belk"'
Autor:
Philip F. Stahel, Kathy W. Belk, Samantha J. McInnis, Kathryn Holland, Roy Nanz, Joseph Beals, Jaclyn Gosnell, Olufunmilayo Ogundele, Katherine S. Mastriani
Publikováno v:
Patient Safety in Surgery, Vol 18, Iss 1, Pp 1-11 (2024)
Abstract Background Patients with unplanned readmissions to the intensive care unit (ICU) are at high risk of preventable adverse events. The Rothman Index represents an objective real-time grading system of a patient’s clinical condition and a pre
Externí odkaz:
https://doaj.org/article/7f8deaa312574edb80f4c62c31f845dd
Autor:
Karolina Zebrowska, Rosa C. Banuelos, Evelyn J. Rizzo, Kathy W. Belk, Gary Schneider, Koen Degeling
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Background: Novel therapies in metastatic cancers have contributed to improvements in survival outcomes, yet real-world data suggest that improvements may be mainly driven by those patient groups who already had the highest survival outcomes. This st
Externí odkaz:
https://doaj.org/article/813f2686994f4af3a3e8c8fc7201b43f
Autor:
Joseph Beals, IV, PhD, Jaime J. Barnes, DO, Daniel J. Durand, MD, Joan M. Rimar, DNSc, Thomas J. Donohue, MD, S. Mahfuz Hoq, MD, Kathy W. Belk, BA, Alpesh N. Amin, MD, Michael J. Rothman, PhD
Publikováno v:
Critical Care Explorations, Vol 3, Iss 4, p e0400 (2021)
Objectives:. Triaging patients at admission to determine subsequent deterioration risk can be difficult. This is especially true of coronavirus disease 2019 patients, some of whom experience significant physiologic deterioration due to dysregulated i
Externí odkaz:
https://doaj.org/article/2a2e647d0785420e937b1c618cb4df91
Publikováno v:
Journal of Health Economics and Outcomes Research, Vol 7, Iss 2 (2020)
**Background/Objective:** The primary objective was to quantify the role of the number of Centers of Disease Control and Prevention (CDC) risk factors on in-hospital mortality. The secondary objective was to assess the associated hospital length of s
Externí odkaz:
https://doaj.org/article/9fe12ea2fec945c28117b3df0d17a41f
Autor:
Kathy W Belk, Peter J. Mallow
Publikováno v:
Journal of comparative effectiveness research. 10(18)
Aim: To conduct a cost–utility analysis of a novel genetic diagnostic test (OUDTEST) for risk of developing opioid use disorder for elective orthopedic surgery patients. Materials & Methods: A simulation model assessed cost–effectiveness and qual
Publikováno v:
American Journal of Cardiovascular Drugs. 20:161-168
Idarucizumab reverses the anticoagulant effect of dabigatran, but few comparative studies have reported on clinical outcomes with idarucizumab. Our objective was to determine the effect of idarucizumab on clinical outcomes. We conducted a retrospecti
Publikováno v:
Journal of Pain Research
Peter J Mallow,1 Kathy W Belk,2 Michael Topmiller,3 Scott A Strassels4 1Health Services Administration, Xavier University, Cincinnati, OH 45229, USA; 2Health Data Analytics, Vizient, Inc., Mooresville, NC 28115, USA; 3HealthLandscape, American Academ
Publikováno v:
Perfusion
Introduction: Historically, perioperative hemoglobin monitoring has relied on calculated saturation, using blood gas devices that measure plasma hematocrit (Hct). Co-oximetry, which measures total hemoglobin (tHb), yields a more comprehensive assessm
Publikováno v:
Expert Review of Clinical Pharmacology. 10:559-565
We compared real-world treatment patterns, resource utilization, and cost of care for patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel + gemcitabine or FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, oxaliplatin).
Autor:
Benjamin Gutierrez, Kathy W. Belk, Deborah P. Lubeck, Christopher M. Blanchette, Christopher Craver, Sandro Rossetti
Publikováno v:
Journal of Medical Economics. 18:303-311
Polycystic kidney disease (PKD) is a clinically and genetically heterogeneous class of genetic disorders characterized by development of renal cysts leading to renal failure and end stage renal disease (ESRD). Autosomal dominant polycystic kidney dis